Is IRadimed Corp. overvalued or undervalued?

As of 31 October 2025, the valuation grade for IRadimed Corp. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 39, a Price to Book Value of 8.54, and an EV to EBITDA of 30.68, all of which are elevated compared to industry norms. In comparison, Artivion, Inc. has a significantly lower P/E ratio of -268.22, while BioLife Solutions, Inc. shows a negative EV to EBITDA of -77.88, highlighting IRadimed's relatively high valuation within its peer group.
Despite the overvaluation, IRadimed Corp. has demonstrated strong performance, with a year-to-date return of 57.70%, significantly outperforming the S&P 500's return of 16.30% over the same period. This strong stock performance may suggest investor confidence, but the high valuation ratios indicate that caution is warranted.